Advertisement

HIV Care Today


The Overlooked Secondary Benefits of PrEP
By Howard Grossman, M.D.
September 18, 2015

Pre-exposure prophylaxis (PrEP) against HIV infection utilizing tenofovir/emtricitabine (Truvada) has been nothing short of revolutionary in changing the landscape of HIV prevention. What has been less discussed are the enormous secondary benefits that have followed the introduction of PrEP.

Read more …


Is PrEP 100 % Effective or 100 % Over-Hyped?
By Tim Lahey, M.D., M.M.Sc.
September 18, 2015

Recently we got great news from a real-world study of HIV pre-exposure prophylaxis (PrEP).

Researchers at San Francisco's Kaiser Permanente Medical Center reported on the real-world experience of 657 people who started PrEP between 2012 and 2015. Over 99% were men who have sex with men, 84% reported multiple sexual partners, and 30% had HIV-positive partners. Together they were observed for over 388 person-years of PrEP use.

Read more …


We're in an HIV Prevention Revolution. Where Is the Excitement?
By Marc-André LeBlanc
September 10, 2015

We're in the midst of an HIV prevention revolution. Over the past few years, we have gained new tools and knowledge to prevent HIV, from pre-exposure prophylaxis (PrEP) to the knowledge that an undetectable viral load dramatically reduces the risk of transmission.

Read more …


Two Drugs With High Prices -- One Is (Surprise!) Good Value, the Other Is Truly a Rip-Off
By Paul E. Sax, M.D.
September 7, 2015

By now, the fact that HCV treatment carries a high price is a fact as well known to the medical and non-medical public as 1) a million dollars doesn't get you much in Manhattan or Bay-area real estate; 2) a Rolex is an expensive way to know what time it is; and 3) even though a Tesla doesn't need gas, buying one won't save you money.

Read more …


Post-Exposure Prophylaxis for HCV Can't Be Cost-Effective -- but We Might End Up Recommending It Anyway
By Paul E. Sax, M.D.
August 23, 2015

An email query from a colleague:

Hi Paul,
Just got a call from one of our surgeons who got a needlestick from a suture needle, small amount of blood. Patient is HCV+. Any post-exposure prophylaxis recommended?

Read more …


Summer HIV and Infectious Disease Highlights
By Paul E. Sax, M.D.
August 17, 2015

Title of this post notwithstanding, the weather in Boston this summer has been great -- mostly warm days, cool nights, low humidity -- hence the energetic jumping pooch in the picture (not mine, click on it for full effect). I just love the phrase, "dog days of summer," and wanted an excuse to use it.

Read more …


The Pain -- and Potential Power -- of Electronic Health Records in One Little Anecdote
By Paul E. Sax, M.D.
August 9, 2015

Here's a scintillating series of events that happened recently on our inpatient consult service.

Read more …


Patching the Leaky Cascade: Report From the 2015 Adherence Conference
By David Fawcett, Ph.D., L.C.S.W.
July 27, 2015

Thirty-three million people are infected with HIV worldwide, but less than 50% receive antiretroviral therapy. This was the stark reality addressed in June at the 10th International Conference on HIV Treatment and Prevention Adherence (Adherence 2015), which is jointly provided by the International Association of Providers of AIDS Care (IAPAC) and the Postgraduate Institute for Medicine (PIM). Every aspect of the ubiquitous treatment cascade was addressed in an effort to stop the "leaks" of people not engaging in treatment, falling out of care or not maintaining viral suppression. While access to prevention and treatment has significantly improved worldwide, certain issues such as stigma still impact prevention and treatment, and gender, age, race and sexual orientation continue to make certain populations vulnerable and in need of interventions tailored to their specific needs.

Read more …


Really Rapid Review: IAS 2015
By Paul E. Sax, M.D.
July 26, 2015

Vancouver will always have a special place in HIV treatment history. It was here, in 1996, that many of us first saw the potential of combination antiretroviral therapy to control this disease.

Read more …


Right Thing, Right Place, Right Time: Utilizing Data to Strengthen the Fight Against HIV
By David Fawcett, Ph.D., L.C.S.W.
July 25, 2015

Because current levels of HIV spending are unsustainable, HIV prevention and intervention efforts must become highly targeted in order to maximize their impact. This was the theme of many presentations at the 10th International Conference on HIV Treatment and Prevention Adherence. The conference, held June 28 to 30 in Miami, Florida, was jointly provided by the International Association of Providers of AIDS Care (IAPAC) and the Postgraduate Institute for Medicine (PIM).

Read more …

 < Prev  |  1  |  2  |  3  |  4  |  5  |  …  |  19  |  Next > 

Get email notifications every time HIV Care Today is updated.



This article was provided by TheBodyPRO.com.
 

Advertisement